Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AutoKinetics-guided antibiotic dosing in sepsis
NL-OMON53354Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Feb 2018
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vancomycin, ceftriaxone, meropenem, ciprofloxacin and cefotaxime in sepsis, sponsored by Vrije University Medical Center. Primary endpoints: PK target attainment in first 24 hours, Beta-lactam PK target and 2 more. Started Feb 2018; status: active, not recruiting.
02
Drugs
vancomycinceftriaxonemeropenemciprofloxacincefotaxime
03
Conditions
sepsis
Beyond the preview
Go deeper on NL-OMON53354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53354.